Curated News
By: NewsRamp Editorial Staff
September 08, 2026
Tonix Pharmaceuticals Promotes Thomas Englese to Chief Commercial Officer
TLDR
- Tonix Pharmaceuticals promotes Thomas Englese to CCO, strengthening leadership to boost TONMYA sales and expand market presence.
- Tonix Pharmaceuticals appoints Thomas Englese as chief commercial officer to oversee sales, marketing, and market access for TONMYA and migraine drugs.
- Tonix Pharmaceuticals advances fibromyalgia and migraine treatments, improving patient access and care with new commercial leadership.
- Tonix's TONMYA is the first new fibromyalgia treatment in over 15 years, now with a dedicated CCO to drive its launch.
Impact - Why it Matters
This news matters for investors and patients alike. It signals Tonix's strategic focus on commercializing its flagship product TONMYA, which could significantly impact the fibromyalgia market. With a seasoned executive leading commercial efforts, the company is poised to expand market access and drive revenue growth, potentially affecting the company's stock performance. For patients, it underscores the availability of a new treatment option that has been long awaited.
Summary
Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP), a fully integrated, commercial-stage biopharmaceutical company focused on central nervous system (CNS) and immunology treatments, has promoted Thomas Englese to Chief Commercial Officer. Englese, previously Executive Vice President of Commercial Operations since September 2024, will now lead the company's commercial strategy and operations for its marketed products, including TONMYA for fibromyalgia and Zembrace SymTouch and Tosymra for acute migraine. President and CEO Seth Lederman praised Englese's instrumental role in building the commercial organization and launching TONMYA, while Englese expressed commitment to expanding access, growing patient and prescriber bases, and increasing sales as the TONMYA launch broadens.
TONMYA is the first new treatment for fibromyalgia in over 15 years, offering hope to millions suffering from this chronic condition. The company's CNS portfolio also includes TNX-2900 for Prader-Willi syndrome and a pipeline of immunology programs, such as TNX-4800 for Lyme disease prophylaxis and TNX-1500 for kidney transplant rejection prevention. Tonix is also exploring TONMYA's potential in Phase 2 trials for major depressive disorder and acute stress disorder. This promotion underscores Tonix's commitment to advancing its commercial capabilities and delivering innovative therapies to patients with high unmet medical needs.
InvestorWire, a specialized communications platform, distributed this press release, which is also available on the company's newsroom. For more information on Tonix Pharmaceuticals, visit their website or follow the latest updates via the provided links.
Source Statement
This curated news summary relied on content distributed by InvestorBrandNetwork (IBN). Read the original source here, Tonix Pharmaceuticals Promotes Thomas Englese to Chief Commercial Officer
